Physician profile
James E Obryon
NPI 1598742512
$12,684.31
in general payments reported to CMS, 2019-2025
57 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,861 · 2020: $1,904 · 2021: $2,625 · 2022: $1,960 · 2023: $1,227 · 2024: $1,495 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,321 · Travel and Lodging: $14.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,320.75 |
| Travel and Lodging | $14.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,169.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,083.34 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $819.50 | 2019-2025 | Repatha, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $774.33 | 2019-2022 | |
| Abbvie INC. | $673.93 | 2019-2025 | |
| Pfizer INC. | $673.56 | 2019-2025 | |
| Lilly USA, LLC | $582.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $570.58 | 2019-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Astellas Pharma US INC | $512.14 | 2019-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $483.65 | 2019-2023 | Seglentis, Livalo |
| Amarin Pharma, INC. | $345.16 | 2019-2022 | |
| Allergan, INC. | $302.86 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $263.49 | 2019-2023 | Trintellix |
| Daiichi Sankyo INC. | $255.29 | 2019-2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $245.45 | 2023-2025 | Voquezna |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Obryon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.